Pharmaceutical News

RSS

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

HTDS update on its H1N1 project status

HTDS- The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary; and other general business matters.

18 Sep 2009

Biomaterial gel for treating spinal cord injury

Research led by a scientist at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has shown injecting biomaterial gel into a spinal cord injury site provides significantly improved healing.

18 Sep 2009

Merck, Wellcome Trust to launch vaccine center in India to produce vaccines for developing countries

Pharmaceutical company Merck and the Wellcome Trust have joined together to create a non-profit, £90-million (about $150 million) research center in India to facilitate the development of new vaccines, "including [those for] neglected diseases for which inadequate or no vaccines exist," Nature News reports.

18 Sep 2009

Quidel's QuickVue Influenza A+B test receives special 510(k) clearance for H1N1 reactivity update

Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.

17 Sep 2009

A not-for-profit mission from Wellcome Trust and Merck to develop affordable vaccines for low-income countries

The Wellcome Trust and Merck & Co., Inc. today announced the creation of the MSD Wellcome Trust Hilleman Laboratories (www.hillemanlaboratories.in), the first of its kind research and development joint venture with a not-for-profit mission to focus on developing affordable vaccines to prevent diseases that commonly affect low-income countries.

17 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

FDA: Manufacturers to include warning of promethazine hydrochloride injection on labels

The U.S. Food and Drug Administration is telling manufacturers of the drug promethazine to include a boxed warning regarding the injectable form of the drug.

17 Sep 2009

LAB Research signs exclusive agreement to extend Korean market

LAB Research Inc. ("LAB", "LAB Research" or the "Company"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced that it has extended its Korean market coverage through a new exclusive agency agreement with Safe Chemicals Co., LTD., a South Korea based consulting company ("Safe Chemicals").

17 Sep 2009

DDI Predict 2009 edition assessing the risk of potential drug-drug interactions released

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the release of the 2009 Edition of DDI Predict. This innovative software application adds a number of enhancements to assess the risk of potential drug-drug interactions including those involving multiple enzymatic pathways.

17 Sep 2009

GENova Biotherapeutics signs collaboration deal with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed a collaboration deal with Beckpharma Ltd.

17 Sep 2009

Glaxo conceals risks: Antidepressant drug Paxil causes birth defects

Antidepressant drug Paxil, which generated about 2.1% of GlaxoSmithKline's total revenue last year, has been known to cause birth defects, but the world's second-biggest drugmaker hid its risks to pump up profits, a Philadelphia court has heard.

17 Sep 2009

Cepacol introduces instant pain relief tablets for children with sore throats

As a leader in the Lozenge Category, Cepacol(R) has announced the introduction of Cepacol(R) Fizzlers(TM), a single symptom sore throat relief product designed specifically for kids.

17 Sep 2009

BioMedReports.Com's news report on CEL-SCI's key developments

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special news report on key developments at CEL-SCI Corporation.

17 Sep 2009

NCPA happy with Baucus' proposals for community pharmacies

The National Community Pharmacists Association (NCPA) commended Senate Finance Committee Chair Max Baucus (D-MT) for including several critical provisions to help community pharmacies better serve patients in the “America’s Healthy Future Act” proposed today.

17 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

FDA issues a complete response letter for Sanofi-aventis' eplivanserin NDA

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the company's New Drug Application (NDA) for eplivanserin (Ciltyri(R)). Eplivanserin was reviewed as a potential treatment for patients with chronic insomnia characterized by difficulties with sleep maintenance.

17 Sep 2009

Weis Markets to hold low-cost flu shot program

Beginning this month, Weis Markets will hold more than 100 low-cost flu shot clinics in its Maryland, New Jersey, Pennsylvania and West Virginia stores. In addition, as part of its WEISCARE Adult Immunization program, many Weis Markets' pharmacies will offer flu shots as an on-going service.

17 Sep 2009

DNage's observational study assesses natural progression of CS in children

Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).

17 Sep 2009